| Similar Articles |
|---|
 |
The Motley Fool
October 17, 2006
Brian Lawler |
See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note.   |
The Motley Fool
August 21, 2010
Kris Eddy |
The Motley Fool's Weekly Editors' Picks Three of the week's most educational, amusing, and enriching articles are available on stock scams, for-profit education, and Buffett's favorites. |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
The Motley Fool
September 28, 2009
Brian Orelli |
The Berkshire of Health Care Johnson & Johnson is becoming the Berkshire Hathaway of health care. In addition to its usual M.O. of bolt-on acquisitions, the health-care giant has recently taken some equity stakes in smaller drug companies. |
The Motley Fool
August 28, 2010
Todd Wenning |
Dividend Report Card: Johnson & Johnson Does this health-care titan's dividend pass the test? |
The Motley Fool
June 25, 2010
Brian Orelli |
The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error. |
The Motley Fool
March 24, 2011
Anand Chokkavelu |
Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund." |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues. |
The Motley Fool
January 17, 2012
Brian Orelli |
Pharma Focus Is Good For Your Portfolio Build your own portfolio. |
The Motley Fool
December 1, 2008
Brian Orelli |
Johnson & Johnson Firms Things Up The health-care giant acquires breast-implant maker Mentor. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
October 13, 2008
Brian Orelli |
Foolish Forecast: J&J's Diversity Counts Views you can use to get clues on tomorrow's news |
The Motley Fool
January 26, 2011
Brian Orelli |
J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot. |
The Motley Fool
July 12, 2011
Todd Wenning |
What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales? |
The Motley Fool
January 8, 2008
Mac Greer |
Fool Video: The Best Stock for 2008, Buffett's Latest, and Bear Market Buys Can Apple continue to produce? Will McDonald's serve up big earnings? Is 2008 the year for Johnson & Johnson? Will Starbucks continue to yield not-so-grande returns? These and other questions are answered in this video. |
The Motley Fool
August 24, 2010
Brian Orelli |
One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well. |
The Motley Fool
May 22, 2009
Brian Orelli |
J&J and Cougar: Meow or Roar? Health-care giant Johnson & Johnson is doing something that many of its investors -- Buffett included -- wouldn't do; it's buying a development-stage drugmaker that has no proven drugs. |
The Motley Fool
April 21, 2010
Brian Orelli |
Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant. |
The Motley Fool
July 9, 2010
Brian Orelli |
Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products. |
The Motley Fool
August 15, 2007
Brian Orelli |
Buffett's Drug Deals During the most recent quarter Berkshire Hathaway has increased their holdings in several battered pharmaceutical and medical stocks. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
July 8, 2011
Brian Orelli |
Half a Breakup Is Better Than No Breakup at All Pfizer keeps two divisions and puts two on the chopping block. |
The Motley Fool
January 13, 2012
Morgan Housel |
5 Companies You Can Buy Today Cheap by the numbers. |
The Motley Fool
February 28, 2011
Brian Orelli |
Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo. |
The Motley Fool
August 11, 2010
David Meier |
Does Bill Miller Think Johnson & Johnson Is Attractive? Johnson & Johnson fits Miller's criteria perfectly. It pays a 3.6% dividend that has been growing 11.1%, on average, for the past five years. |
The Motley Fool
December 17, 2009
Brian Orelli |
This Acquisition Hears, Smells, and Tastes Soooo Good Johnson & Johnson picks up an ear, nose, and throat medical device maker. |
The Motley Fool
August 24, 2010
Matt Koppenheffer |
How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale? |
The Motley Fool
August 17, 2010
April Taylor |
Buffett Buys: A New Stock and Doubling Down on J&J Berkshire Hathaway's Warren Buffett was back in buying mode during the second quarter; the big moves were the addition to Berkshire's stake in Johnson & Johnson and establishment of a new position in Fiserv. |
The Motley Fool
June 30, 2010
Brian Orelli |
Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
The Motley Fool
May 28, 2010
Brian Orelli |
How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem? |
The Motley Fool
August 27, 2010
Eben Esterhuizen |
Warren Buffett's Trades: Visualizing the Oracle's Portfolio Tweaks A look at Berkshire Hathaway's recent moves. |
The Motley Fool
December 1, 2010
Brian Orelli |
We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell. |
The Motley Fool
July 31, 2007
Nathan Parmelee |
Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business. |
The Motley Fool
November 9, 2006
Philip Durell |
The Best Blue Chip for 2007: Berkshire Hathaway Management doesn't get any better than Warren Buffett. It's hard to find a better lower-risk investment or a better blue chip than Berkshire Hathaway. |
The Motley Fool
July 2, 2009
Brian Orelli |
Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company. |
The Motley Fool
January 28, 2011
Anand Chokkavelu |
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo. |
The Motley Fool
June 15, 2011
Brian Orelli |
Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market. |
The Motley Fool
August 18, 2009
Morgan Housel |
Warren Buffett Goes Buying ... and Selling Warren Buffett's moves over the years would leave you well ahead of the pack. Here's a rundown of Berkshire's latest buys and sells. |
The Motley Fool
July 22, 2011
Matt Koppenheffer |
Could Eli Lilly's Stock Double Your Money? With concerns swirling around the big pharma companies, could it be time to buy Eli Lilly? |
The Motley Fool
March 14, 2011
Brian Orelli |
This Deal Is No Dog Eli Lilly picks up Johnson & Johnson's European animal-health business. |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
The Motley Fool
October 27, 2009
Brian Orelli |
Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions? |
The Motley Fool
November 17, 2009
Brian Orelli |
Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
February 23, 2009
Brian Orelli |
The DOJ v. Johnson & Johnson The U.S. Department of Justice is joining a lawsuit against the health care giant over the company's marketing of heart failure drug Natrecor. |
The Motley Fool
March 17, 2009
Brian Orelli |
Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace. |
